Page 11234..1020..»

Archive for the ‘Personalized Medicine’ Category

The 5th Annual Companion Diagnostics Forum on Oct 27-28 gathers scientists, clinicians, regulators and industry professionals for two days of…

Thursday, October 22nd, 2020

HOLMDEL, N.J., Oct. 20, 2020 /PRNewswire/ -- The 5th Annual Companion Diagnostics Forum will take place Tuesday and Wednesday, October 27-28, 2020. Register at

"The online Companion Diagnostics Forum is focused on the need for Companion Diagnostics to grow and keep pace with novel developments in Pharma," said Event Chair Oscar Puig from Eli Lilly, adding, "We are providing access to key people in this important field that are working every angle to ensure patients get the personalized medicine they require."

Keynote speaker Steve Anderson, CSO from Covance, explained that"Companion diagnostics are a critical component for delivering on the promise of precision medicine. This conference brings together industry leaders to discuss and review innovations and emerging applications in companion diagnostics."

Some of the therapeutic areas that will be covered are Oncology, ALS and trauma-related disorders. Education, regulations and adoption in clinical applications will be discussed at this year's forum. Speakers will addresshow these various areas are combining to bring better healthcare to patients.

Ronnye Schreiber, CEO, PlanetConnect and event organizer, said, "We are pleased that we can offer this custom virtual environment to ensure that the Forum could move forward even though we cannot meet in-person."

See a complete agenda and register online at

About PlanetConnect The Companion Diagnostics Forum is produced by PlanetConnect, a certified woman-owned conference producer and event production company with more than 25 years experience running scientific symposia for pharmaceutical, research, IT and manufacturing organizations. With decades of experience providing cost-effective, creative solutions, PlanetConnect enables companies to focus on making meaningful connectionsnot just meetings.

Contacts:Event Chair: Oscar Puig, Translational Medicine, Oncology Late Stage Development, Eli Lilly [emailprotected] Event Manager: Ronnye Schreiber, CEO, PlanetConnect, [emailprotected]

SOURCE PlanetConnect

See the rest here:
The 5th Annual Companion Diagnostics Forum on Oct 27-28 gathers scientists, clinicians, regulators and industry professionals for two days of...


Dr Messoud Ashina Talks Through the 5-Year Safety and Efficacy Data on Erenumab – Managed Markets Network

Thursday, October 22nd, 2020

Data from a 5-year open-label treatment period on the safety profile of erenumab (Aimovig) showed the treatment helped patients with episodic migraine (EM) achieve a sustained reduction in the number of monthly migraine days (MMD) and the number of days in which therapies were needed for acute migraines.

The set of data we have now obtained is very, very important from the clinical point of view,said Messoud Ashina, MD, PhD, professor of neurology in the Faculty of Health and Medical Sciences at theUniversity of Copenhagen and lead investigator of the study.

Erenumab, which wasapprovedby the FDA in 2018, is a calcitonin gene-related peptide (CGRP) inhibitor administered via self-injection once a month. The treatment blocks the CGRP receptor, which is believed to play a crucial role in migraine. Erenumab can be injected as a 70- or 140-mg dose in adults with migraine. Results from the phase 2 study were initially published during the Migraine Trust Virtual Symposium.

In an interview with The American Journal of Managed Care (AJMC), Ashina reviewed the findings and discussed potential next steps for the treatment.

The sustained efficacy of erenumab is integral, as many migraineurs experience a wearing off of treatment effects after 3 or 4 months on a single preventive therapy, Ashina explained. Furthermore, the study found that erenumabs safety profile was nearly identical to that observed during the double-blind period, and no additional adverse reactions were reported. The most common adverse events included nasopharyngitis and upper respiratory tract infections.

Although roughly 70% of the 216 patients enrolled in open-label phase of the study reported long-term efficacy, researchers do not yet know what accounts for the heterogeneity in terms of response. So far, we havent found any predictors for efficacy, and we need more research and more new studies to explain why this group of patients does not respond to monoclonal antibodies, Ashina said.

Currently, the Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine (OASIS EM) trial is underway. When it comes to the treatments effects in pediatric populations, Ashina expects to see similar long-term results. This is one of the areas with a huge unmet need for new treatments, he said. Medications currently available for children can have side effects and adverse events, making some specialists hesitant to prescribe preventive treatments to younger populations.

Based on the safety and tolerability that we see in an adult population [with erenumab], we would expect to also see positive results in children, as this population also has a high frequency of episodic migraine, Ashina said. But lets see, because we havent seen data yet.

OASIS EM is estimated to be completed in August 2025.

In addition to studies on erenumabs efficacy in children, Ashina noted that future studies ought to be conducted on predicting the treatments efficacy in patients. If predictive markers of efficacy are found, this will also pave the way for personalized medicine in the future.

The second issue is with erenumab and also other monoclonal antibodies is about safety and tolerability in patients with different comorbidities, Ashina explained. As most clinical trials do not include patients with serious comorbidities, real-world data will be essential to understand the effects of erenumab on these patients.

Registry studies can also be used to track any effects that monoclonal antibody treatments may have on pregnant women. Erenumab is currently contraindicated during pregnancy, but you can imagine that when you have a drug with a long half-life, and if you get pregnant, it might theoretically affect the baby, Ashina said.

Excerpt from:
Dr Messoud Ashina Talks Through the 5-Year Safety and Efficacy Data on Erenumab - Managed Markets Network


Research Antibodies and Reagents Market worth $14.1 Billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

Thursday, October 22nd, 2020

CHICAGO, Oct. 20, 2020 /PRNewswire/ -- According to the new market research report "Research Antibodies and Reagents Marketby Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blotting, Flow Cytometry), Application (Proteomics, Drug Development), End User - COVID-19 Impact - Global Forecast to 2025",published by MarketsandMarkets, the global market size is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period.

The growth is due to evolution of market owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global market is expected to witness significant growth in the coming years.

Browse in-depth TOC on "Research Antibodies and Reagents Market"

220 Tables 45 Figures 278 Pages

Download PDF Brochure:

The COVID-19 outbreak has boosted research activity due to efforts to understand the dynamics of the infection. We estimate that the major share of research antibody and reagent manufacturing, along with personalized medicine, will grow at a stable pace in the next five years. Due to the increase in research activity, both the availability of funding for research and the demand & manufacturing of reagents and antibodies are expected to grow. As companies after pandemic have scaled up their operations for testing and tracking the infection of COVID-19. This has given a chance for growth in profits for companies operating in the NGS and PCR markets. The growth in revenue is 57%, as COVID-19 testing has increased with the use of the latest technology of genetic and molecular testing. The shift in demand for research for COVID-19, neurobiology, and oncology has created a huge scope for testing solutions, such as western blotting, flow cytometry, ELISA, and drugs for researchers and laboratories.

The antibodies segment is expected to grow at the highest CAGR during the forecast period

Based on product, the research antibodies market is segmented into reagents and antibodies. The antibodies segment is expected to grow at highest CAGR in forecast period. This is due to the research-use antibodies offer high specificity and selectivity and are used ubiquitously in biochemical and medical research for protein-target identification, regulatory characterization, and discovery.

The primary antibodies segment is accounts for the largest share of the research reagents market

Based type, the research reagents market is segmented into primary antibodies and secondary antibodies. The primary antibodies segment held the largest share of the global research antibodies market in 2019. This segment is witnessing a strong growth due to the use of these antibodies in numerous types of assay formats. Their accuracy in biomarker detection and their high specificity and sensitivity are also driving their adoption

The media & sera reagent is expected to account for the largest share of the market, by type, in 2019

Based type, the research antibodies and reagents market is segmented into media &sera, stains & dyes, fixatives, buffers, solvents, enzymes, probes and other reagents. The media & sera reagent segment held the largest share of the global research antibodies market in 2019. The large share of this segment is primarily attributed to the use of these components in all types of assays, cell cultures, and techniques.

The western blotting segment is expected to account for the largest share of the market, by technology, in 2019

Based on technology, the research antibodies market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. Western blotting segment is expected to grow at highest CAGR in forecast periods (2020-2025). This is due to the high adoption of this technique in proteomic and genomic research. The results achieved are easy to interpret, unique, and unambiguous, making it suited for evaluating levels of protein expression in cells, monitoring fractions during protein purification, and comparing the expression of a target protein from various tissues.

The pharmaceutical & biotechnology segment is expected to grow at the highest CAGR during the forecast period

Based on end user, the research reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. The growth of this segment is due to antibodies provide a gold standard for the detection of a biomolecule or a pathway and are even capable of detecting specific changes in potential drug targets. Additionally, highly specific reagents are used to measure pharmacokinetic parameters in the preclinical and clinical development of biological drugs. The increasing demand for personalized medicine and government initiatives in this sector are the key market drivers for this segment.

Get 10% Customization on this Research Report:

The APAC market is expected to grow at the highest CAGR during the forecast period

The Asia Pacific research reagents market is expected to grow at the highest CAGR from 2020 to 2025.The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also, high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics.

The prominent market players are Thermo Fisher Scientific (US), Merck Group (Germany), Abcam plc (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports:

Browse Related Reports:

Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025

Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets' flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected]Research Insight: Visit Our Website: Content Source:

SOURCE MarketsandMarkets

Read more from the original source:
Research Antibodies and Reagents Market worth $14.1 Billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire


World Cord Blood Day 2020 Speakers to Present Revolutionary CAR-NK Cell Therapy, Potential Treatments for Covid-19 Related MIS-C and Advantages of…

Thursday, October 22nd, 2020

TUCSON, Ariz., Oct. 21, 2020 /PRNewswire/ --Registration is now open for the World Cord Blood Day 2020 virtual conference (register free on Eventbrite) featuring world renown cord blood transplant doctors and cellular therapy researchers. To be held on November 17th, the virtual conference will provide an opportunity for healthcare professionals, expectant parents, and students to learn about life-saving cord blood stem cells via a mix of livestream and on-demand sessions. The public is also invited to participate in a wide variety of free educational events being held around the globe by WCBD Official Participants (see listings on

Attendees of the virtual conference will learn how cord blood has been used in more than 40,000 stem cell transplants since 1988 to treat over 80 life-threatening diseases including leukemia, sickle cell anemia, thalassemia, and lymphoma. Ground-breaking research will also be presented by scientists who are discovering cord blood's full potential in CAR-NK immunotherapy, the emerging field of regenerative medicine to potentially treat autism, cerebral palsy, Covid-19 related MIS-C and more. Keynote presentations will be made by Dr. Joanne Kurtzberg (Duke Department of Pediatrics, Duke Center for Autism and Brain Development), Dr. Katy Rezvani (MD Anderson Cancer Center), Dr. Jonathan Gutman (University of Colorado), Dr. Leland Metheny (Case Western Reserve University), and Monroe Burgess (Quick Specialized Healthcare Logistics). Dr. Moshe Israeli (Rabin Medical Center) will lead the opening session on HLA matching and cord blood.

In addition, a panel of industry experts will discuss how cord blood has come to the forefront during the Covid-19 pandemic. Increasingly, stem cells transplant doctors are using cord blood units collected well before the pandemic and now available for immediate use. Attendees will also hear from Dr. David Hall and Vanessa Yenson, who both beat cancer thanks to cord blood transplants.

To view the full agenda, please visit:

Organized and hosted by Save the Cord Foundation (501c3 non-profit), this year's event is officially sponsored by Quick Specialized Healthcare Logistics. "We're proud to be a sponsor of World Cord Blood Day for the fourth year in a row. This year is sure to be very informative and exciting, providing the latest information from some of the industry's top doctors and researchers. We're humbled to play a role in the research and development of cord blood derivative therapies by providing logistics supply chain solutions to cord blood, biotech and pharmaceutical companies worldwide," said David Murphy, Executive VP of Quick's Life Science Division.

Inspiring Partners this year include the Cord Blood Association (CBA), Be the Match (NMDP), World Marrow Donor Association (WMDA-Netcord), AABB Center for Cellular Therapy and Foundation for the Accreditation of Cellular Therapy (FACT).

Visit to learn how you can participate and/or host an event. Join us on social media using the hashtags: #WCBD20 and #WorldCordBloodDay.

About Save the Cord Foundation

Save the Cord Foundation (a 501c3 non-profit) was established to advance cord blood education. The Foundation provides non-commercial information to parents, health professionals and the public regarding methods for saving cord blood, as well as current applications using cord blood and the latest research. Learn more at

About Quick Specialized Healthcare Logistics

Quick is the trusted logistics leader serving the Healthcare and Life Science community for almost 40 years. Quick safely transports human organs and tissue for transplant or research, blood, blood products, cord blood, bone marrow, medical devices, and personalized medicine, 24/7/365. Quick's specially trained experts work with hospitals, laboratories, blood banks and medical processing canters, and utilize the safest routes to ensure integrity, temperature control and chain of custody throughout the transportation process. Learn more at

Media Contact:Charis Ober[emailprotected]520-419-0269

SOURCE Save the Cord Foundation

The rest is here:
World Cord Blood Day 2020 Speakers to Present Revolutionary CAR-NK Cell Therapy, Potential Treatments for Covid-19 Related MIS-C and Advantages of...


Top 10 Companies Combining AI and Drug Discovery in… –

Thursday, October 22nd, 2020

Rapid advances in artificial intelligence over the last decade have the potential to revolutionize how drugs are developed. These are the top 10 companies in Europe that are working to make AI drug discovery a reality.

Drug development is a slow and increasingly expensive process. Artificial intelligence (AI) has the potential to make the drug development process quicker, cheaper and more efficient. This technology can make scanning vast libraries of chemical compounds that might be able to treat a certain disease easier, can speed up the analysis of biomedical information from the literature, and can help companies recruit the most suitable patients for clinical trials. AI can also streamline the design of better drugs and incorporate new data, such as genomic analysis, to help personalized medicine become a reality.

There are now an increasing number of companies that are using AI to improve drug discovery and development in a variety of different ways. We enlisted the help of experts in the industry to select the top European companies in this area. As ever, these are in no particular order.

Location: Oxford, UKFounded: 2012

Exscientia was one of the first companies to apply AI technology to drug discovery. Its focus is to quickly identify and optimize drug candidates that are more likely to succeed in clinical trials than those selected by conventional means.

The companys first AI-designed drug candidate, to treat obsessive-compulsive disorder, began human testing in a phase I trial earlier this year. It took Exscientia 12 months to bring the candidate to clinical trials rather than the average time of around five years. More recently, the company announced it was working with US partners to apply its technology to searching for drug candidates to treat Covid-19.

The Oxford-based company has deals with Bayer, BMS, Sanofi, GSK, and Celgene to co-develop new drugs for a variety of diseases and conditions. Exscientia also closed an impressive 54M Series C round at the end of April, in the midst of the Covid-19 pandemic.

Location: Cambridge, UKFounded: 2014

Healx uses AI to analyze extensive medical research data with the goal of repurposing and finding new combinations of existing drugs to treat rare diseases such as fragile X syndrome, Angelman syndrome and muscular dystrophy.

The company raised a 50.8M Series B round in October 2019. Shortly after, Healx announced it was committing 17M to run its Rare Treatment Accelerator program, allowing patient groups a chance to work with the company to find new treatments for rare diseases.

The companys most advanced program, a drug repurposed for fragile X syndrome, took less than two years to reach clinical trials instead of the normal five-to-seven years this process usually takes. Like many others, Healx is using its technology to search for treatments for Covid-19.

Location: London, UKFounded: 2013

BenevolentAI has developed an AI platform that can identify new drug target candidates for any therapeutic area. The company has its own pharmaceutical team to investigate potential leads and develop their own products. The company began life as Stratified Medicine before changing its name in 2016.

BenevolentAI is working in a variety of disease areas including Alzheimers and ALS. While the company is working on its own drug candidates, it also has various partnerships including with the big pharma companies AstraZeneca and Novartis. BenevolentAI recently hit the news when it discovered a potential treatment for Covid-19, the existing rheumatoid arthritis drug baricitinib, which has shown to improve and speed up the recovery of hospitalized patients with Covid-19.

The company technically reached unicorn status in 2018 when it achieved a valuation of 1.7B after a big fundraising. However, the companys valuation suffered significantly when Neil Woodford, who had been a major investor, was forced to wind up his fund in 2019, though the valuation has since improved again.

Location: Eschborn, GermanyFounded: 2011

Unlike other companies in the field, Innoplexus doesnt develop its own pharmaceuticals, Instead, the firm gives pharma companies, biotechs, contract research organizations and life sciences professionals access to its data platform to help them design better drugs and improve decision making throughout the drug development process.

The company uses AI and blockchain to search published papers, online data from presentations, symposiums and conferences, clinical trial data, and publicly available hospital data as well as unpublished datasets.

Last spring, Innoplexus closed a Series C round worth an undisclosed amount in the double-digit millions. In March, The company released an analysis of hundreds of clinical studies that suggested a treatment for Covid-19 consisting of hydroxychloroquine combined with a variety of other drugs, including Gileads antiviral remdesivir.

Location: Copenhagen, DenmarkFounded: 2008

Evaxion has a focus on infectious diseases and oncology. The company has developed two AI platforms that can be used to create immunotherapies by selecting the antigens that are most likely to produce strong immune responses against infections or cancer.

One of the platforms is used for the development of personalized cancer immunotherapies. In April 2019, the company dosed its first patient with its lead candidate, a therapeutic vaccine targeting solid tumors. The other platform can identify vaccine antigens that trigger protective responses against pathogenic bacteria in less than a day.

At the end of last year the company raised 16M. As with most of the other companies in this space, Evaxion has launched its own Covid-19 effort an AI platform designed to enable a faster response to emerging viral pandemics by identifying potential vaccines and taking them to clinical trials within just 13 weeks.

Location: Frankfurt am Main, GermanyFounded: 2016

Genome Biologics has a focus on RNA interference therapies for cardiovascular and cardiometabolic diseases. The company uses an AI platform to assist in identifying suitable drug targets and also allows 2D and 3D investigation of RNAi disease targets in a variety of animal models.

Genome Biologics was developed with support from the Johnson & Johnson Innovation Labs Incubator in Beerse, Belgium, where the company has an office. The company is still young, but has raised 2.5M in grant and seed funding to further develop its technology. Its lead candidate treatment is expected to start phase I/II testing in heart failure patients next year.

Genome Biologics recently joined Blue Knight, a collaboration of companies created by Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) in the US, that aims to anticipate potential global health threats and infectious diseases.

Location: Lyon, FranceFounded: 2010

Novadiscovery uses data from preclinical and clinical studies to model a drugs effect on patients and predict whether it will be successful or not at treating a specific disease. The company has worked on a wide range of indications including liver disease, respiratory disease, hepatitis, immuno-oncology, and cardiovascular disease.

Compared to other similar companies, Novadiscovery is able to work with small and large data sets alike. The AI platform is also designed to be transparent and allow users to check if the tool is working correctly.

The company raised 5M in Series A funding earlier this year to develop its technology further and offer it to clients as a cloud-based service where users pay for access.

Location: Dublin, IrelandFounded: 2014

Nuritas uses its AI platform to search and analyze large libraries to find potential drug candidates or nutritional additives. In particular, the company focuses on identifying and developing peptide drugs.

Although it has a strong focus on developing nutritional supplements, Nuritas is also using its platform to develop potential drug candidates. The company is currently investigating a fibrosis target that is implicated in a number of diseases including liver, renal and cardiac disease.

Nuritas has raised 53.9M since it was founded in 2014 and has collaborations with big players such as Nestle, Johnson & Johnson and BASF. The company has also joined the Covid-19 effort and is searching for antiviral peptides that could block the virus causing Covid-19, SARS-CoV-2, from infecting cells or locally reduce lung inflammation without the need for complete immunosuppression.

Location: Budapest, HungaryFounded: 2015

Turbine has a focus on cancer. The company has built a dynamic computational model of human cell biology that uses AI to predict how cancer cells respond to drugs and finds new targets, biomarkers and therapies. By running thousands of simulated experiments, this technology can dramatically speed up drug development.

Turbine is currently focusing on DNA damage repair targets, found in 30% of cancers, particularly in patients resistant to other therapies. The company secured 3M in seed funding at the end of last year and has partnered with German big pharma Bayer to develop new applications for its existing cancer drugs. It also has its own preclinical-stage drug development programs in development.

Location: Tel Aviv, IsraelFounded: 2016

Tel Aviv-based CytoReason is definitely worth a mention on this list. The company has one of the largest libraries of human molecular data in the world. It uses this information to create computational cell models of the human immune system to advance drug development.

For example, an analysis of melanoma biopsies using the companys AI platform identified that patients who responded to the drug nivolumab had higher numbers of adipocyte cells than those who did not. The company has also discovered several potential new targets for this cancer that had not previously been investigated.

CytoReason has not revealed its funding to date, but has high-value partnerships with several big pharma companies including Pfizer, GSK and Roche focusing on drug development in immunology.

Visit link:
Top 10 Companies Combining AI and Drug Discovery in... -


Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market – PRNewswire

Thursday, October 22nd, 2020

PALM BEACH, Fla., Oct. 21, 2020 /PRNewswire/ --Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market.Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options areresulting in discovery of new therapeutic options for cancer treatment. A recent industry reportfrom MarketsAndMarkets projected that the global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. The growth of this market is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, increasing adoption of immunotherapy drugs over conventional treatments, and a favorable approval scenario. However, timeline issues, side-effects, and manufacturing complexities and a high attrition rate in the product development cycle are expected to challenge market growth. Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE: ATNM), AstraZeneca PLC (NASDAQ: AZN), Bristol Myers Squibb (NYSE: BMY), Northwest Biotherapeutics(OTCQB: NWBO), Merck (NYSE: MRK).

The report said that: "Based on type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapies. The monoclonal antibodies segment accounted for the largest share of the global immunotherapy drugs market in 2019. This large share can be attributed to their high specificity and fewer side-effects, increasing focus on personalized medicines, initiatives by industry players, and the rising target disease incidence and patient pool On the basis of therapeutic area, this market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the global immunotherapy drugs market, by therapeutic area, in 2019. The large share of this segment can be attributed to the growing prevalence of cancer, rising research activity in this area, and reimbursement coverage for immunotherapies for oncology."

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) BREAKING NEWS: Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to study Iomab-ACT, Actinium's CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) or diffuse large B-cell lymphoma (DLBCL). MSK will lead this first of its kind study to utilize targeted radiopharmaceutical ARC-based lymphodepletion to replace chemotherapy-based conditioning prior to CAR T-cell therapy. The study will assess the feasibility of using Iomab-ACT targeted lymphodepletion prior to MSK's 19-28z CAR-T and assess safety and efficacy outcomes relative to results with MSK's CAR-T 19-28z in patients who had received chemotherapy-based lymphodepletion prior to CAR-T administration.

Results published in the New England Journal of Medicine with MSK's 19-28z CD19 CAR-T in 53 patients with R/R B-ALL reported complete remissions in 83% (44/53) of patients. Median event-free survival (EFS) was 6.1 months and median overall survival (OS) was 12.9 months at a median follow up period of 29 months (range 1 65 months) for all patients. Patients with low disease burden, defined as less than 5% blasts in the bone marrow, had markedly enhanced outcomes with increased median EFS of 10.6 months and median OS of 20.1 months. There was a 26% (14/53) rate of Grade 3 of greater cytokine release syndrome (CRS), with 1 patient death as a result, and 42% of patients experienced Grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS). In addition to improved duration of response and survival, patients with low disease burden prior to receiving CAR T-cell therapy had lower rates of CRS and neurotoxicity.

"We are excited to be collaborating with MSK on this trial as they are aleader in the field of cellular therapies. We selected MSK's 19-28z CAR T-cell therapy for this NIH grant funded collaboration because ithas produced high response rates in patients with relapsed or refractory B-ALL who have previously undergone several lines of standard therapy. However, toxicities such as cytokine release syndrome and neurologic toxicity, as well as durability of response, remain a challenge as is the case with many other CAR T-cell therapies" commented Dr. Mark Berger, Actinium's Chief Medical Officer. "Iomab-ACT enables the delivery of targeted radiation that selectively and specifically targets immune cells, including those implicated in the CAR-T-associated toxicities of cytokine release syndrome and neurotoxicity. We are hopeful that this study will demonstrate improvements in safety and outcomes with MSK's CAR 19-28z as a result of Iomab-ACT targeted lymphodepletion and that this will allow clinicians to make important improvements in patients' ability to receive CAR T-cell therapies."

CAR-T is a type of cellular therapy in which a patient's own (autologous) T-cells are genetically engineered outside of the body to target the patient's cancer cells and which are then reinfused back into the patient to seek out and kill cancer cells. Currently there are 2 approved CD19 targeted CAR-T therapies, which both require chemotherapy-based conditioning to deplete the patient's lymphocytes, known as lymphodepletion, and many other CAR-T constructs in development that also use chemotherapy conditioning for lymphodepletion.

Iomab-ACT targets cells that express CD45, an antigen found on immune cells such as lymphocytes and macrophages as well as leukemia and lymphoma cancer cells and delivers the radioisotope warhead iodine-131 to achieve cell depletion. Iomab-ACT is intended to deplete CD45+ immune cells such as macrophages that are implicated in CAR-T related toxicities and may also have an anti-tumor effect on chemo-refractory cancers. Iomab-ACT is a low dose extension of Actinium's lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant. Preclinical data supporting Iomab-ACT's application in targeted lymphodepletion prior to ACT such as CAR-T was recently published in the journal Oncotarget ( In addition, clinical data with trace doses of Iomab-B has shown transient, reversible lymphodepletion in patients and drug clearance pharmacokinetics that fit within the vein to vein time of CAR-T manufacturing and administration.

Sandesh Seth, Actinium's Chairman and CEO, said, "This clinical trial collaboration with MSK is a strong step forward for Actinium and our targeted conditioning program. The 19-28z CAR-T has already produced promising data and we look forward to working with MSK to explore Iomab-ACT's potential to reduce toxicities and improve patient outcomes. As we advance towards the SIERRA interim analysis in the fourth quarter, we are focused on the continued expansion of our ARC-based targeted conditioning program for bone marrow transplant and cell and gene therapies with the goal of providing targeted conditioning regimens that are less toxic and more effective than current chemotherapy-based conditioning. With these therapies being administered in a select number of concentrated centers, we see a large and growing market opportunity where our ARC-based targeted conditioning can improve outcomes and increase access to these important curative treatment options." Read this full release and more news for ATNM at:

Other recent developments in the biotech industry include:

AstraZeneca PLC (NASDAQ: AZN) AstraZeneca's TAGRISSO(osimertinib) recently announced it has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years.

Bristol Myers Squibb (NYSE:BMY) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval ofOpdivo(nivolumab) for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based combination chemotherapy. The European Commission (EC), which is authorized to approve medicines for the European Union (EU), will now review the CHMP recommendation.

"This positive CHMP opinion underscores the potential ofOpdivoin the EU treatment landscape for esophageal squamous cell carcinoma, with the ATTRACTION-3 trial showing clinically meaningful survival coupled with a favorable safety profile," said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. "We look forward to the EC's final decision, which could mark the first time an immunotherapy is approved for any upper gastrointestinal cancer in the EU. We remain committed to continuing to explore the potential benefits ofOpdivoin earlier settings of esophageal cancer."

Merck (NYSE: MRK), known as MSD outside the United States and Canada, recently announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company's investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or older received V114 or PCV13 followed by PNEUMOVAX23 one year later. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13 (day 30), immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination. Results from both studies are based on opsonophagocytic activity (OPA) responses a measure of vaccine-induced functional antibodies. V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies.

Northwest Biotherapeutics(OTCQB: NWBO), a biotechnology company developing DCVaxpersonalized immune therapies for solid tumor cancers, recently announced that the database for the Phase III trial of DCVax-L for Gliobastoma has been locked. With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage.

The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates and, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty five hundred dollars for news coverage of the current press releases issued by Actinium Pharmaceuticals, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:[emailprotected] -+1(561)325-8757


View original post here:
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market - PRNewswire


HPE, AMD and EuroHPC Partner for Massive LUMI Supercomputer – HPCwire

Thursday, October 22nd, 2020

Not even a week after Nvidia announced that it would be providing hardware for the first four of the eight planned EuroHPC systems, HPE and AMD are announcing another major EuroHPC design win. Finnish supercomputing center CSC revealed today that its forthcoming LUMI system commissioned under the auspices of EuroHPC will be built by HPE using AMD processor technology. With a target Linpack performance of 375 petaflops, LUMI is the second of three planned pre-exascale machines under EuroHPC to have its hardware detailed. The system also breaks new ground in energy efficiency.

The system

LUMI is based on the HPE Cray EX supercomputer architecture, and will harness next-generation AMD Epyc CPUs and AMD Instinct GPUs. Storage will include 7 PB of accelerated flash-based storage (LUMI-F, utilizing a Cray ClusterStor E1000 storage system); an 80 PB Lustre file system (LUMI-P); and 30 PB of encrypted object storage (LUMI-O). LUMIs primary GPU-driven partition (LUMI-G) will be supplemented by a data analytics partition with 32 TB of memory and additional GPUs (LUMI-D), as well as a CPU partition featuring around 200,000 AMD Epyc CPU cores. LUMI will use HPE Slingshot networking.

LUMIs main partition is expected to deliver over 550 peak petaflops of computing power, just above (current Top500 leader) Fugakus 513.8 peak petaflops. Committed Linpack performance, meanwhile, is 375 petaflops (shy of Fugakus 415.5). This makes LUMI the most powerful of the five planned EuroHPC systems that have been detailed so far: Italys Leonardo system is expected to deliver over 200 peak petaflops; Luxembourgs Meluxina, over 18; the Czech Republics EURO IT4I, 15.2; and Slovenias Vega, 6.8.

Energy efficiency & siting

LUMI will support research from ten countries, comprising a new LUMI consortium: Belgium, the Czech Republic, Denmark, Estonia, Finland, Iceland, Norway, Poland, Sweden and Switzerland. The consortium says that LUMI will enable more precise climate models; advanced AI applications in areas like self-driving vehicle development; large-scale social science analytics; personalized medicine research; and much more. Up to 20 percent of LUMIs capacity will be reserved for European industry and small- and medium-sized enterprises (SMEs).

The system will be installed in a new datacenter at CSCs campus in Kajaani, Finland, where CSC says the system will take up roughly the size of a tennis court. The datacenter is expected to be ready by Q4 2020; the first phase of LUMI, by Q2 2021; and the second phase of LUMI, by Q4 2021. LUMI will use 100 percent renewable energy (thanks to local hydropower) and its waste heat will be used to supply approximately 20 percent of the yearly district heating needs of its host town, resulting in a stated net negative carbon footprint of 13,500 tons of CO2 equivalent per year.

HPE says that LUMI will use approximately 8.5 megawatts, which translates into an extremely efficient 44.1 gigaflops per watt. For context, this is nearly double the efficiency of thecurrent Green500 leader, MN-3, which delivers 21.1 gigaflops per watt. Extrapolating LUMIs numbers out, an exascale system would require just around 22.7 megawatts well within the 40-megawatt limit targeted by the planned U.S. exascale systems (a goal that requires a minimum efficiency of 25 gigaflops per watt), and close to the ambitious 20-megawatt exascale goal set by the U.S. Defense Advanced Research Project Agency (DARPA) in the early 2010s. With HPE supplying those three exascale systems as well, this may be the first real preview of those systems computational efficiency.

Once operational in mid-2021, the LUMI supercomputer will be one of the most competitive and green supercomputers in the world, said Anders Jensen, executive director of EuroHPC. Such [a] leadership-class system will support European researchers, industry and [the] public sector in better understanding and responding to complex challenges and transforming them into innovation opportunities in sectors like health, weather forecasting or urban and rural planning.

LUMIs total cost of ownership through 2026 is expected to be approximately 200 million ($237.1 million), of which 140 million ($165 million) will go toward the supercomputer itself. This cost will be split between the European Commission (100 million), Finland (50 million) and the remaining nine countries in the LUMI consortium (50 million).

The EuroHPC roadmap

LUMI is the second EuroHPC system so far that is being built by HPE (with the other being EURO IT4I). Leonardo, Meluxina and Vega, meanwhile, are all being built by French IT firm Atos. As a U.S. company, HPE appears to have successfully wooed EuroHPC with promises to bring some of its operations across the pond: HPE will be manufacturing liquid-cooled Cray EX supercomputers and Apollo systems in its Kutn Hora factory in the Czech Republic (where EURO IT4I will be based), and the company has also committed to establishing a Center of Excellence in Europe that will provide R&D services and expertise in support of exascale readiness.

Three of the eight planned EuroHPC systems are yet to be detailed: the four-petaflops PetaSC system, hosted by Sofia Tech Park in Bulgaria; the ten-petaflops Deucalion system, hosted by the Minho Advanced Computing Center in Portugal; and the 200-petaflops MareNostrum 5 system, hosted by the Barcelona Supercomputing Center in Spain. By process of elimination, MareNostrum 5 will be the last of the three pre-exascale systems to be fully announced. For the third machine, the tendering process is in its very final phase now, Jensen said, so there will be announcements on that in the coming weeks.

LUMI is the latest in a series of wins for HPEs Cray EX systems, which will serve as the basis for the three planned U.S. exascale systems (Aurora, El Capitan and Frontier) and Australias most powerful supercomputer (just announced this week). Conspicuously absent, however, are mentions of the European Processor Initiative (EPI) and its planned first-generation Rhea CPUs, ostensibly slated for 2021. Jensen maintains that the EPI continues to factor into the future of EuroHPC.

The ambition is that when we get to the exascale systems which is what we will be discussing in the coming years that EPI will deliver a processor that we can base at least one of the upcoming exascale systems on, he said.

Header image: concept art of the LUMI supercomputer. Image courtesy of CSC.

Read this article:
HPE, AMD and EuroHPC Partner for Massive LUMI Supercomputer - HPCwire


Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360 – GlobeNewswire

Thursday, October 22nd, 2020

BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360, being held virtually on October 26-27, 2020.

Breakout Session Details: Title: Tracking Personalized Medications in Gene and Cell TherapyDate/Time: October 26, 2020 at 3:00 p.m.

For more information on the 8th annual CMO Summit 360, or to register, please click here.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage in patients with COVID-19 who are experiencing respiratory failure, for which the Company recently initiated a clinical trial as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. and slated to begin a comprehensive Phase 2b trial in the U.S. during 4Q20 for the treatment of coronary microvascular dysfunction (CMD); and CLBS14, a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA). For more information on the company, please visit


Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate

Media:W2O GroupChristiana PascalePhone:

Go here to read the rest:
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360 - GlobeNewswire


Healthtech investors on the holy grail of remote care and a new way of thinking about health IT – GeekWire

Thursday, October 22nd, 2020

GeekWire Summit panelists, clockwise from top left: Threshold co-founder Emily Melton; Canaan Partners general partner Nina Kjellson; and Biomatics Capital co-founder Julie Sunderland.

Investor interest in healthcare technology is on the rise amid a pandemic that has put a spotlight on telemedicine, patient monitoring, and more. Global VC funding to digital health companies reached a record $10.3 billion through the first nine months of this year, up 43% year-over-year, according to Mercom Capital Group.

At the GeekWire Summit on Tuesday, we brought together three investors who are spending time at the crossroads of technology and healthcare. Read on for takeaways from the conversation, which included Threshold co-founder Emily Melton, Biomatics Capital co-founder Julie Sunderland, and Canaan Partners general partner Nina Kjellson. Dr. Robert Overell, president of Foundation BioVenture, moderated the discussion.

No slowdown: Nearly all industries braced for the worst when COVID-19 began spreading. But the investors agreed that activity within the healthcare tech market is now accelerating. Sunderland called out the progress being made with COVID-19 therapeutics and vaccines, as well as advances with telemedicine and remote care.

Its been a good signal of the thesis we all have, which is that we live at an extraordinary time in terms of innovation in biopharma and innovation in the application of technology to healthcare, Sunderland said.

Melton added: We are not seeing a slowdown now. If anything, its actually faster than its ever been and one of the most competitive markets Ive ever been involved in.

Holy grail:As remote care becomes more common, collecting reliable data from patients outside the clinic or hospital and making it seamless will be paramount. Kjellson called it the holy grail of remote care.

Whether its for clinical use to practice better medicine, or for clinical trials to get better data, that is a trend accelerated by COVID and is here to stay and will drive value going forward, she said. From an investment basis, if we can improve that reliably, we should be looking for those opportunities and investing in those opportunities. It will make better medicines, it will drive better clinical trials, its good for the healthcare system.

Melton said thats particularly true if the right value-based incentive business models are also put in place so people are encouraged to participate in the data collection process.

Sunderland said shes excited about using data to drive behavior change, but the lack of payment mechanisms is a roadblock to capturing value and building new businesses.

When you run into that wall of trying to sell tools into the payer system, and you realize how hard it is and how long those enterprise cycles are and how hard it is to get to scale even if you were creating value from patients, you get discouraged pretty quickly, she said.

Not just computers for healthcare: The relationship between tech and healthcare is rapidly evolving as digital tools and services are applied across various sectors.

Melton called out Livongo, the digital disease management company that announced its $18.5 billion acquisition by Teladoc Health in August. The Livongo solution includes both hardware such as monitoring devices, and software that provides data insights and enables patient communication.

We get excited about those intersections, said Melton, whose firm invested in Livongo. Its not just thinking about only investing in software companies or services businesses or medical devices companies, but looking at where to bring those pieces together to create unique experiences that drive more value.

Kjellson added that many biotech companies are now built on the power of informatics, whether its processing data or doing faster DNA sequencing. She also brought up Vineti, which sells software that helps manage the supply chain and manufacturing process for biotech firms developing personalized treatments. The company counts both Threshold and Canaan Partners as investors.

Vineti is trying to be the enterprise solution to modernize how you connect all of these nodes from the couriers to clinicians to the manufacturers so you have a really safe, seamless, transparent process for how precision medicine gets delivered to patients, Kjellson said. Thats a very different way of thinking about health IT than computers for healthcare.'

[The full interview with the healthtech investors, and other GeekWire Summit sessions, are available on-demand exclusively to attendees of the virtual event.Learn more and register here.]

Read the rest here:
Healthtech investors on the holy grail of remote care and a new way of thinking about health IT - GeekWire


Victory Square Technologies Portfolio Company enters into Sales & Distribution agreement with the Canadian Gaming Association – GlobeNewswire

Thursday, October 22nd, 2020

CGA members will be able to access on-site rapid testing for Covid-19 subject to Health Canada approvals

VANCOUVER, British Columbia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (VS Health or the "Company") a portfolio company of Victory Square Technologies Inc. ("Victory Square'') (CSE:VST) (OTC:VSQTF) (FWB:6F6) has entered into an agreement with the Canadian Gaming Association (CGA), a national trade association representing the leading operators and suppliers in Canadas casino gaming and lottery industry subject to Health Canada approval.

The Company announced on October 6, 2020 that it had submitted all formal documents and research for Health Canada approval of its proprietary Safetest Covid-19 Rapid test. This sales, distribution and testing agreement will enable VS Health to assist the members of one of Canadas largest hospitality industry associations ensuring the health and safety of the 180,000 employees that make up the gaming industry in Canada. Before the industry shut down in March, Canadian casino and bingo operators had over 50 million unique visits annually to their properties.

This Safetest Covid-19 Rapid Testcomplement will allow each participating property to access rapid, easy, efficient and cost-effective daily Covid-19 Rapid tests to ensure employees are not infected with the Covid-19 virus, which will in turn keep workplaces safe. The test may also be administered to customers, subject to Health Canada approvals.

We are very pleased to engage with Victory Square Health, said Paul Burns, President and CEO of the Canadian Gaming Association. We believe that providing access to rapid testing, like the Safetest Rapid Test product, is one of the most important tools to help reopen our economy and to allow for greater confidence in increasing capacities in venues across the hospitality industry.

I am delighted with this important agreement with the CGA so that Victory Square Health may realize its goal of commencing distribution of its exclusive Rapid Test kits on a national scale, said Victory Square CEO Shafin D. Tejani. The gaming and entertainment industries have been adversely affected by this pandemic and we are confident that our products and testing services will enable these properties to reopen and increase capacity through our Covid-19 tests. We look forward to providing our Safetest Rapid Test kits and testing services to all companies affected by Covid-19 following Health Canada approvals so that they can get their teams back to work and help grow our economy.

Victory Square Health is committed to assisting Canadians and Canadian organizations. The company recently announced a strategic partnership with the Canadian Police Association and its members across Canada.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansens Disease, Brucellosis, HTLV and blood sample screening tests.


The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

*These figures have been vetted by the Canadian Gaming Association

Go to: and sign up for VSTs official newsletter at

On behalf of the board,

Shafin Diamond TejaniChief Executive OfficerVictory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact Alex TziliosEmail: alexandros@victorysquare.comTelephone: 778-867-0482

Media Relations Contact Howard Blank, DirectorEmail: howard@victorysquare.comTelephone: 604-928-6066


Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.

VST's sweet spot is the cutting-edge tech that's shaping the 4th Industrial Revolution. Our portfolio consists of 23 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn't just another investor. With real skin in the game, we're committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best build, innovate and disrupt. In 24-36 months, you'll scale and be ready to monetize.

What we do differently for investors

VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they're unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit


The Canadian Gaming Association (CGA) is a national trade association that works to advance the evolution of Canadas gaming industry. The associations mandate is to promote the economic value of gaming in Canada; use research, innovation, and best practices to help the industry advance; and create productive dialogue among stakeholders.

Forward Looking Statement

This news release contains forward-looking information within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as believes, expects, anticipates, estimates, intends, plans, continues, project, potential, possible, contemplate, seek, goal, or similar expressions, or may employ such future or conditional verbs as may, might, will, could, should or would, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

See more here:
Victory Square Technologies Portfolio Company enters into Sales & Distribution agreement with the Canadian Gaming Association - GlobeNewswire


The evolving role of technology and informatics in healthcare – VatorNews

Thursday, October 22nd, 2020

Healthcare technology and data are taking on more diverse roles than ever before

Technology changes healthcare treatments and solutions every day. With rapidly developing life-saving tech and informatics systems, healthcare providers are better able to accumulate and apply data for beneficial results.

Modern tech makes this evolving system of informatics possible. A single medical study can gather 100 terabytes of data thats as much as 21,300 DVDs worth of information. This data can then be analyzed and applied using smart tech to improve the state of healthcare for everyone.

In the course of the healthcare evolution, technology and data are taking on more diverse roles than ever before. Now, nursing informatics is being developed to protect patient health, safety, and privacy. 3D-printing techniques are making it possible to reproduce organs. And telematics is allowing for more comfortable, accessible care, especially during the pandemic.

Here, we explore how the evolving roles of technology and informatics are shaping the healthcare industry.

Nursing informatics, safety, and privacy

Nursing is one of the most vital careers to maintain a healthy society. As the frontline of healthcare treatment, nurses manage the difficult task of juggling patient care with data systems. In the course of this work, they discover, treat, and record patient health.

By integrating evolving informatics technology into the traditional role of nursing, these caretakers of public health are better able to find effective solutions while protecting sensitive patient data. Healthcare data is a primary target of cybercriminals due to its valuable nature. Because of this, nurses shoulder the evolving burden of managing data protections alongside care provisions.

In the scope of this protection, the specialist role of nursing informatics has emerged to help bridge the gap between the technical aspects of nursing and the clinical side. A nursing informatics specialist combines technology with the care and communicative aspects of nursing to customize software and hardware for care solutions.

Through pairing data and smart tech with the human aspect of care, care solutions are evolving. Informatics in nursing makes this possible.

Take, for instance, the pathology and personalized medicine solutions being created by healthcare company Paige. The smart tools this company is producing can assist in nursing and pathology to present genomic information at a glance for better immediate communication and treatment. Through computer analysis of tissue, Paiges tech can give care providers diagnostic information almost instantly without destroying a genomic sample.

Solutions like these are made possible by big data. A database is analyzed, then an AI system guides nurses or pathologists to a correct condition or treatment plan with better accuracy.

This assists in communication with other healthcare providers while allowing nurses to provide more specialized immediate care. On the whole, the evolution of nursing informatics tech is making care more efficient.

3D-printing and the future of healthcare

Like something out of science fiction, 3D-printing is arriving on the healthcare scene to create previously unfathomable care solutions. The role of 3D-printing tech is evolving into a life-saving component of regenerative and personalized medicine. With the ability to print organs for transplant using simple tissue and blood draws, this technology is the future of healthcare.

Dr. Anthony Atala and his team were able to grow human organs and tissues using additive manufacturing processes and collagen substrates. Combining human cells with 3D-printing allowed them to form replacement organs like heart valves, trachea, livers, and even genitalia.

The lifesaving implications of this tech are astounding. With a relatively simple design and usability process, medical professionals can more safely conduct transplants. Building personalized organs removes the painful threat of bodily rejection. Additionally, waitlists for transplants could become a thing of the past. New organs grown directly with a persons bodily tissue mean miraculous recovery for millions of patients.

Telematics and accessibility

In a world facing a pandemic, finding innovative healthcare solutions like these is more important than ever. Evolving technology makes healthcare accessibility possible. Regardless of geographic location, vulnerable patients can receive treatment in the form of telemedicine and telematics.

Telematics gathered and applied through virtual conferencing have proven especially vital due to COVID-19, where each healthcare visit presents a risk in itself. As a result, the field of telemedicine is growing all the time.

Care providers using smart tools can meet virtually with patients, analyze issues, diagnose problems, and assign treatment. In the pandemic environment, this means no risky face-to-face meetings where they can be avoided. This keeps some of the most vulnerable individuals safe.

Telemedicine is a viable solution for a wide number of healthcare visits. Vein restoration through telemedicine is even possible, with physicians able to virtually assess varicose veins through a video call, connecting with patients in real-time to provide treatment.

Providers like TeraPractice make virtual care a focus of their practice. This allows them to provide convenient access to patients while managing costs for everyone. With such a beneficial combination of results, telematics and telemedicine is evolving as a key element of healthcares future.

Final thoughts

Issues abound in the healthcare system that have yet to see bipartisan agreement. This makes progress on the regulatory side of healthcare slow. However, new technology that addresses issues like accessibility means improvements in care for millions.

The role of technology while always vital has evolved to prove that the future of healthcare is already here. Through smart tools, nurses can better integrate data and communicative solutions. Meanwhile, 3D-printing has real life-saving potential. In the wake of a global pandemic, these tools alongside telematics make healthcare safer, more accessible, and more affordable for everyone.

(Image Source: Pexels)

Here is the original post:
The evolving role of technology and informatics in healthcare - VatorNews


Personalized Medicine Market to Eyewitness Massive Growth by 2025 – re:Jerusalem

Thursday, October 22nd, 2020

Latest Report Available at Advance Market Analytics, Space Tourism Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.

Major Players in This Report Include

Quest Diagnostic (United States), Laboratory Corporation (United States), Becton, Dickinson, and Company (United States), Abbott Laboratories (United States), Pfizer Inc. (United States), Siemens Healthineers AG (Germany), CardioDx, Inc., (United States), Atrium Innovations Inc. (Canada), QIAGEN (Germany), Proteostasis Therapeutics, Inc. (United States), Asuragen (United States), Illumina, Inc. (United States) and Amgen Inc. (United States)

Free Sample Report + All Related Graphs & Charts @ :

Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Employee Engagement Software Market various segments and emerging territory.

Brief Overview on Global Personalized Medicine

Personalized medicine diagnosing, monitoring, and giving the treatment to the individual according to the segmentation of disease risks and characteristics of each patient. This approach relies on the scientific research results and how the persons molecular nature along with genetic profile makes them susceptible to the particular disease. The research on personalized medicine id increasing the ability to predict the medical treatment which can be safe and effective to people and which can not.

The Global Personalized Medicine Market segments and Market Data Break Down are illuminated below:Type (Diagnostic, Therapeutics, Medical Care, Nutrition, Wellness), Application (Hospitals, Molecular Diagnostic Laboratories and Testing Centers, Academic Institutes), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Dietary Care Centers, Others), End User (Patients and Consumers, Health Care Providers, Health Care Providers, Biopharmaceutical Companies, Others)

Market Trend

Market Drivers

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Enquire for customization in Report @:

Strategic Points Covered in Table of Content of Global Personalized Medicine Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Global Personalized Medicine market

Chapter 2: Exclusive Summary the basic information of the Global Personalized Medicine Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Global Personalized Medicine

Chapter 4: Presenting the Global Personalized Medicine Market Factor Analysis, Post COVID Impact Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2014-2019

Chapter 6: Evaluating the leading manufacturers of the Global Personalized Medicine market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2020-2025)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Global Personalized Medicine Market is a valuable source of guidance for individuals and companies in their decision framework.

Data Sources & Methodology

The primary sources involves the industry experts from the Global Personalized Medicine Market including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Companys Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.Get More Information: benefits does AMA research studies provides?

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317

Connect with us at

Continue reading here:
Personalized Medicine Market to Eyewitness Massive Growth by 2025 - re:Jerusalem


New support for personalised medicine and cell therapy – Health Europa

Tuesday, October 6th, 2020

Researchers at the Massachusetts Institute of Technologys (MIT) research enterprise Critical Analytics for Manufacturing Personalized Medicine (CAMP) have been awarded Intra-CREATE grants from the National Research Foundation (NRF).The grants will support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries.

Krystyn Van Vliet, co-lead Principal Investigator at Singapore-MIT Alliance for Research and Technology (SMART) CAMP, and Professor of Materials Science and Engineering at MIT, said: Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART.

In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society.

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, Massachusetts Institute of Technology (MIT), and National University of Singapore (NUS). The team will seek to establish first principles-founded, and statistically confident models of, glaucoma progression in patients, which will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better targeted treatments.

MIT Mechanical Engineering Professor Barbastathis, co-leader of the research and Principal Investigator at SMART CAMP said: We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction.

The second research project, Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), University of Cambridge, and MIT.

The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project aims to achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimised engineering methods to prepare cells and biomaterials for treatment.

Chew Sing Yian, Principal Investigator at SMART CAMP and Associate Professor of the School of Chemical and Biomedical Engineering, and Lee Kong Chian School of Medicine, at NTU said: Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many, said Hanry Yu, co-lead Principal Investigator at SMART CAMP.

Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the healthcare industry and society.

Follow this link:
New support for personalised medicine and cell therapy - Health Europa


Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology – Managed Markets Network

Tuesday, October 6th, 2020

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations, said Karen Winkfield, MD, PhD, incoming executive director, Meharry-Vanderbilt Alliance.


AJMC: In the era of precision medicine, what can oncologists do to ensure that newer therapies are the right choice for minority patients?

Dr Winkfield: Precision oncology has really come a long way, and I do think that oftentimes people think about it as just genetic testing or genomic testing. That's important, and we do know that there's a gap, even in terms of testing, for some things as simple as an oncotype for breast cancer patients. We know that Black patients are not getting the oncotype test at the same rate as other racial and ethnic groups.

So, really, just making sure that there's access is one thing that can be important. Whether it be partnering with some of the testing facilities to make sure that there is opportunity for individuals who may be underinsured or uninsured to gain access to some of these precision oncology tests, that would be wonderful.

The other thing is making sure people understand, again, community engagement. I'm going to keep coming back to that, because patients need to understand the importance of it and know that they're not being a guinea pig, etc, but that we want to make sure that their treatment is personalized. The personalization is not just to them as an individual, but also to their tumor and what their tumor might be doing. So, that communication is important as well.

So, sometimes it may require a second biopsy. So, you can imagine, if a person has gone through therapy and then their tumor is not responding, and you say, "Oh, we need to get some more tissue," there can be some misunderstandings about that. So, really being open with your patients about the rationale and the reason for getting additional tissue, but, again, making sure that patients don't have very high out-of-pocket cost is one of the things that I think will go a long way to improving access to patients of color and other underserved populations to precision oncology.

Read more:
Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology - Managed Markets Network


OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO – PRNewswire

Tuesday, October 6th, 2020

BINYAMINA, Israel, Oct. 5, 2020 /PRNewswire/ -- OncoHost, a global leader in host response profiling for improved personalized cancer therapy, announced today that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress - ESMOthis Friday, October 9th at 17:20 PM CEST.

The presentation will show how through the analysis of host response profiles (i.e. the patient's reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

"Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC)," said Prof. Yuval Shaked. "OncoHost's studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients."

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shaked's presentation willinclude a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This year's event will be held virtually on October 9-10.

About OncoHost

OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology today resistance to therapy. OncoHost's Host Response Profiling platform (PROphet) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.

For more information, visit

Follow OncoHost onLinkedIn

OncoHost Media Contact: Ellie HansonFinn Partners [emailprotected]+1 929-222-8006


Read the original here:
OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress - ESMO - PRNewswire


OncoHost Data on Host Immunotherapy Response to be Presented This Week – Technology Networks

Tuesday, October 6th, 2020

OncoHost, announced on 5th October that Professor Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion Israel Institute of Technology, will deliver a presentation titled A Proteomics-Based Platform for Predicting Response to Immunotherapy and Personalizing Treatment Plans at the MAP 2020 Virtual Congress - ESMO this Friday, October 9th at 17:20 PM CEST.

The presentation will show how through the analysis of host response profiles (i.e. the patients reaction), oncologists may be able to harness this information to better predict clinical outcomes and suggest the ideal combination treatment with immunotherapy.

Despite major clinical success, immunotherapy treatments have demonstrated efficacy in only a small proportion of patients with non-small cell lung cancer (NSCLC), said Prof. Yuval Shaked. OncoHosts studies have indicated that individual host response to anti-cancer treatment can generate pro-tumorigenic activities and support tumor re-growth and spread. It is therefore vital to analyze and earlier predict host response to treatment in order to improve outcomes and reduce unnecessary side effects experienced by so many patients.

Using machine learning (ML)-based analysis and algorithms to identify highly predictive cohort-based proteomic signatures in patients, personalized response prediction can be used to improve precision medicine in oncology. Personalized treatment plans can then be created through information based on cohort-based statistical analysis, personalized adaption and finally, translation to clinically relevant targets.

Prof. Shakeds presentation will include a real-life case study on whom a Host Response profile analysis was performed, and will be followed by a live Q&A.

MAP is the leading congress in precision medicine in oncology in Europe, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration. This years event will be held virtually on October 9-10.

Excerpt from:
OncoHost Data on Host Immunotherapy Response to be Presented This Week - Technology Networks


Comparing the benefits of scooter-sharing vs. bike-sharing – MIT News

Tuesday, October 6th, 2020

While ride-sharing services like Grab, Uber, and Gojek have become a pervasive part of life, many countries in the Asia Pacific region are still unconvinced when it comes to micro-mobilities such as bike and scooter sharing. While the convenience offered by these is great, especially in this Covid-19 era when people may remain wary of crowding in buses and metro trains, there is a need for in-depth knowledge of these new transportation options to help guide policy and regulation.

A group of scientists in the Senseable City Lab at MIT and the Future Urban Mobility (FM) Interdisciplinary Research Group at the Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, set out to better understand the phenomenon and inform policy-making through a comparative analysis of bike-sharing and scooter-sharing activities in Singapore.

The researchers shared their findings in a paper titled Understanding spatio-temporal heterogeneity of bike-sharing and scooter-sharing mobility published in the journal Computers, Environment and Urban Systems. The study is based on real usage records containing location and time of departures and arrivals in two distinct areas in Singapore.

We constructed historical trajectories of the bike-sharing and scooter-sharing trips and compared usage patterns of the two systems at the Marina Bay area and the NUS campus, says Rui Zhu, a postdoc at SMART FM. Our results showed increased sharing frequency and decreased fleet size for scooter-sharing, suggesting that it performs better than bike-sharing.

More specifically, the sharing frequency was increased from less than one time per day for bike-sharing to more than three times per day for scooter-sharing, but the researchers believe that can be improved even further to create a more profitable service.

The study also found that shared scooters in Marina Bay were frequently left away from their designated parking spaces or charging stations, indicating costly and labor-intensive maintenance since employees need to collect and transport scooters between stations continuously. However, the statistics also showed that over 28 percent and 26 percent of trips departed from and arrived at non-stations respectively, suggesting that users actually utilized most of the inappropriately returned scooters.

In addition, the study revealed quantitative changes in trips over time, distances, and duration, and the influence of weather on the demand of micro-mobilities.

In Singapore and a few other cities, dockless bike-sharing systems rose and fell in just one year, followed by an explosion of docking scooter-sharing systems. But we didnt have the necessary insights for appropriate business and policy decisions, Zhu explains. Our study goes deeper into the problems and possibilities of micro-mobility sharing and suggests how these services can be improved.

To facilitate a sustainable scooter-sharing service, the researchers suggest optimizing the fleet size of stations and their locations, regulating returning behaviors more strictly, enabling scooters to have autonomous repositioning functionality, and increasing the useful battery life of scooters.

To increase battery life, they suggest installing a photovoltaic module on scooters for solar charging during trips and parking time or equipping conventional dock-based stations with grid charging or solar charging platforms, allowing for an environmentally friendly solution that will be able to reduce carbon footprints.

While the business model and user behavior greatly impact the success of mobility-sharing services, government policy also plays a significant role. Supportive policies or regulations on controlling fleet sizes and limiting usage to discrete areas are huge drivers for the sustainable development of the new transportation modes. With this study, SMARTs researchers hope to fill existing gaps in knowledge about micro-mobility sharing to help inform policy decisions.

SMART was established by MIT in partnership with the National Research Foundation of Singapore (NRF) in 2007. SMART is the first entity in the Campus for Research Excellence and Technological Enterprise (CREATE) developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, performing cutting-edge research in areas of interest to both. SMART currently comprises an Innovation Center and six Interdisciplinary Research Groups: Future Urban Mobility, Antimicrobial Resistance, BioSystems and Micromechanics, Critical Analytics for Manufacturing Personalized-Medicine, Disruptive and Sustainable Technologies for Agricultural Precision, and Low Energy Electronic Systems.

The Future Urban Mobility group harnesses new technological and institutional innovations to create the next generation of urban mobility systems to increase accessibility, equity, safety, and environmental performance for the citizens and businesses of Singapore and other metropolitan areas, worldwide.

SMART research is supported by the NRF and situated in CREATE.

See more here:
Comparing the benefits of scooter-sharing vs. bike-sharing - MIT News


Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers -…

Tuesday, October 6th, 2020

Oct. 6, 2020 05:30 UTC

STRASBOURG, France & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies and BostonGene Corporation (BostonGene), a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a strategic collaboration for two ongoing Phase 1 clinical trials of TG4050, an individualized therapeutic vaccine for ovarian and head & neck cancers based on Transgenes proprietary myvac platform and NECs AI-driven Neoantigen Prediction System in Europe and the United States.

Transgenes myvac platform brings together a series of highly innovative technologies, such as viral genome engineering, to achieve high-speed modular manufacturing of bespoke immunotherapies.

TG4050 is an individualized cancer vaccine based on the myvac platform; it is based on an optimized viral platform for cancer vaccination and integrates NECs artificial intelligence capabilities. This therapeutic vaccine aims at stimulating the immune system of patients to induce a T-cell response against tumor-specific antigenic alterations, called neoantigens. These neoantigens are derived from genomic mutations and selected using NECs Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. TG4050 has been designed to target up to 30 patient-specific neoantigens. Transgene is sponsoring two Phase 1 trials that are expected to deliver a first proof of concept of this virus-based individualized approach.

As part of the collaboration, BostonGene will conduct genomic and transcriptomic analyses of primary patient tumors collected from patients enrolled in these two clinical trials to identify predictors of response to TG4050 and the cancer cell-intrinsic and -extrinsic factors that may mediate each patients response to the vaccine. BostonGenes platform integrates the genomic and transcriptomic analyses to simultaneously assess the activity of the tumor and the microenvironment through the identification of significant somatic alterations, evaluation of gene expression, estimation of tumor heterogeneity and classification of the microenvironment.

BostonGene generates a Tumor Portrait Report, involving the data-driven, visually appealing and self-explanatory tumor schematics elegantly depicting tumor activity, tumor cellular composition, and functionality of the immune-microenvironment and other tumor-associated processes. The comprehensive report will provide insights into the individual oncogenic state and immunogenicity of the patients tumor.

BostonGenes unique solution and deep expertise in Next Generation Sequencing (NGS) analysis provide us with the detailed profiles of a tumor and its micro-environment. These Tumor Portrait Reports will help us look at our patient data in light of the current published evidence and could help us accelerate the development of TG4050, said ric Qumneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene. This novel way of analyzing patient data is part of an ambitious translational program that supports the development of our myvac platform. By integrating these types of approaches into our studies, we seek to build an integrated framework for the use of viral-based immunotherapeutics.

NEC looks forward to strengthening its collaboration with BostonGene through these trials of TG4050. BostonGenes advanced analysis of NGS among cancer patients provides excellent profiling that we believe will add important insight into the understanding of each patients tumor environment and how it reflects on the clinical outcomes of our treatment, said Osamu Fujikawa, Senior Vice President at NEC Corporation.

BostonGene is proud to support Transgene and NEC during these critical Phase 1 clinical trials, said Nathan Fowler, MD, Chief Medical Officer at BostonGene. This collaboration represents our ongoing commitment to improve immunotherapy options and transform personalization of treatment for cancer patients.

About TG4050 TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgenes myvac technology and powered by NECs longstanding artificial intelligence (AI) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NECs Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.

TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed for each patient and can be produced in a very short time frame.

This best-in-class candidate is being evaluated in two Phase 1 clinical trials for patients with ovarian cancers (NCT03839524) and HPV-negative head and neck cancers (NCT04183166).

About myvac myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to stimulate the patients immune system, recognize and destroy tumors using the patients own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded Investment for the Future funding from Bpifrance for the development of its platform myvac. TG4050 is the first myvac-derived product being evaluated in clinical trials.

About NEC's Neoantigen Prediction System NEC's neoantigen prediction utilizes its proprietary artificial intelligence (AI), such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house major histocompatibility complex (MHC) binding affinity prediction trained on public and proprietary datasets. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

About Transgene Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Companys clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform).

With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO collaboration with AstraZeneca.

Additional information about Transgene is available at:

Follow us on Twitter: @TransgeneSA

About NEC Corporation NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of Orchestrating a brighter world. NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at

About BostonGene Corporation BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGenes unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGenes mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at

Transgene disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Companys activities, perspectives, financial situation, results, regulatory authorities agreement with development phases, and development. The Companys ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Companys actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (Facteurs de Risque) section of the Universal Registration Document, available on the AMF website ( or on Transgenes website ( Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

View source version on

Read the original:
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers -...


Managing the President’s COVID-19 – American Council on Science and Health

Tuesday, October 6th, 2020

The treatment given to POTUS is the abstraction we all desire personalized medicine. Just the right treatment, at the right time, in the right way. Of course, physicians' day-to-day dilemma is translating guidelines and treatments tested upon populations into efficacious care for the individual sitting across from your desk. And that dilemma is compounded when you deal with VIPs

It is not March; when the virus didn't respond to the treatments that had always worked so well for influenza - we threw everything we had at the problem. While we have made significant progress in treating COVID-19, I do not believe we have a set-in-place protocol for what to do when. There is a broad outline of medications that may reduce symptoms, improve outcomes, and reduce the length of stay lots of ingredients, lots of chefs, but no classic recipe.

All of the medications that the President has been publically acknowledged as receiving reduce symptoms.

Ethical medicine, "shared decision making" between patient and physician requires that I provide you with options, state which I feel is the best approach and why, and together we choose a path forward. The President's care, as with most VIPs, involves lots of chefs. Many chefs with nuanced opinions that by consensus, majority vote, or eminence eventually become a treatment plan. [1] One of the difficulties in treating VIPs, in general, is that in many instances, they believe their eminence extends to being a chef too. They can be very "hands-on" when it comes to choosing treatments and what to pursue.

The patient applies any factors they feel are relevant in that calculus. I think it is apparent that the President has included a political component to his choices. This is not the time to appear weak physically or emotionally. His motorcade to his supporters is an example of powerful eminence in action. As a rule, hospitals don't allow you to leave for a few hours and return; in many cases, chronic smokers with significant addiction to nicotine are not allowed to go outside for a cigarette.

Of course, it takes two to make a medical decision; you still need a physician. Can we reasonably believe that the phrase "an abundance of caution" has not impacted their clinical judgment? Additionally, by my count, the President has had at least three physicians, including his private one, since taking office. The idea that he has a deep enough long-term relationship with any of them that would allow for considered choice is silly; in that way, the President echoes some of our behavior, honoring primary care in word but not deed.

Words matter and their meaningvariessignificantly from one context to another. Consider Chris Christie, who "checked himself in" to a hospital over the weekend. Hospitals are not hotels; you don't check-in; you are admitted to the hospital by an attending physician who has determined you have met the admission criteria. You only would describe admission to the hospital as checking-in to make it seem more an optional vacation choice, less a medical need.

Or the announcement that the President may go home to continue care, you shouldn't take that to mean he is like a typical COVID-19 patient being discharged from the hospital; unless, of course, that patient has a fully equipped Emergency Department and physicians standing by in their home.

It is a fool's errand to guess at the President's clinical status based on his receiving treatment. Whether he received supplemental oxygen doesn't necessarily mean he was more ill or that the doctors acted out of an abundance of caution. What is supplemental oxygen, 2 liters/min or 8, nasal prongs, or face mask? We cannot tell.

He is receiving personalized care, not care from some guidelines that haven't even been formulated. His treatment, like ours, is or should be, is personalized to his needs. It may very well be that his perception of his non-medical needs overrides his physicians' medical judgment, but that is a problem all doctors and patients face.

[1] One of the problems for VIPS is that, in some cases, "too many cooks do spoil the soup." If you don't believe me take a look at themedical decisionssurrounding President Garfield, "At least a dozen medical experts probed the president's wound, often with unsterilized metal instruments or bare hands, as was common at the time." Or look at thecare of the Shah of Iran, whose cancer was treated by the world's best cardiac surgeon, with a very poor outcome.

Read more:
Managing the President's COVID-19 - American Council on Science and Health


AI tool created to guide colorectal cancer care with more precision – Scope

Tuesday, October 6th, 2020

A new modeling tool may be able to help doctors assess which treatments are best for individual patients with colorectal cancer. The artificial intelligence program analyzes a patient's disease details -- such as the stage of cancer and other chronic conditions -- and compares those details to other colorectal cancer cases to predict the patient's chance of surviving past 10 years.

"Predicting survival of cancer patients as a means to help determine treatments is not new," said Jean Emmanuel Bibault, MD, PhD, a radiation oncologist who led the study. "But current standard techniques are not very accurate, and we're hoping that by using AI we can bring more precise information to doctors as they make crucial decisions about care."

Predicting a cancer patient's survival time lends valuable insight into the best course of treatment for both the long and short term, helping to determine what is likely most suitable.

The online tool works by assessing 32 details about an individual patient, such as age, the stage of the cancer, exercise habits, cholesterol levels, history of chronic disease and much more.

After these details are input into the tool, the algorithm predicts how long that person might live and reports a number in years. The tool also provides context, citing the top reasons for its calculation, such as the stage of the cancer, the patient's age at diagnosis, or how the patient was initially treated.

"From a physician's point of view, we want to know how well our patients are going to do from the get-go. We're looking at two main things: how to choose the right therapy, and if we can alter their destiny," said Daniel Chang, MD, professor of radiation oncology, who is an author of the study.

"Some folks have a bit of a nihilistic point of view," he continued, "that survival is determined by the genetics of your cancer and of your body. But the question is: Can anything we, as doctors, do change that outcome if we do it sooner or do it differently from the start? That's where I see a lot of value for this research."

An abstract on the research appeared online inGut.

Bibault, Chang and professor of radiation oncology, Lei Xing, PhD, devised the algorithm powering the prediction tool with data made available through the National Institutes of Health, from thousands of de-identified patients who have or had colorectal cancer at various stages and are of varying ages.

The team trained the algorithm to track survival of thousands of patients, in conjunction with the details of their disease and some details about their course of treatment. In this way, the algorithm uses the outcomes and survival rates of past cohorts to calculate the chance of survival for future patients.

So far, the tool has been about 90% accurate in predictions it made on 472 patient cases that were not used to train the tool. The tool has not been used in a clinical setting.

"The treatments that we have nowadays are becoming more and more specialized, targeted, in many cases intensified. And the reality is that not everybody is going to benefit from new treatments, therapies or technologies in the same way," said Chang.

"This algorithm could allow us a better shot at personalized medicine, and enhance our ability to tailor the treatments to be as appropriate as possible," he added.

Although patients could use the tool on their own, Bibault said the ideal application would be for doctors and patients to use the tool together. That way, doctors would be able to contextualize the result and answer any patient questions.

The team's goal is to enhance the algorithm's accuracy and to find other applications for it.

"We have laid the foundation for this model," said Bibault, "and we're hopeful it can apply to other cancer types as well."

Photo by National Cancer Institute

Read more:
AI tool created to guide colorectal cancer care with more precision - Scope


Page 11234..1020..»

2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick